[HTML][HTML] SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature
AM Becker, KH Dao, BK Han, R Kornu, S Lakhanpal… - PloS one, 2013 - journals.plos.org
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized
by defective immune tolerance combined with immune cell hyperactivity resulting in the …
by defective immune tolerance combined with immune cell hyperactivity resulting in the …
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene …
…, JZ Forstot, MJ Maricic, KH Dao… - The Journal of …, 2010 - jrheum.org
Objective. To assess safety and clinical outcomes in patients with inflammatory arthritis after
intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector …
intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector …
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
…, CM Chiang, S Zhang, A Amod Sathe, C Xing, KH Dao… - Nature cancer, 2020 - nature.com
EGFR inhibition is an effective treatment in the minority of non-small cell lung cancer (NSCLC)
cases harboring EGFR-activating mutations, but not in EGFR wild-type (EGFRwt) tumors. …
cases harboring EGFR-activating mutations, but not in EGFR wild-type (EGFRwt) tumors. …
Systemic lupus erythematosus management in pregnancy
KH Dao, BL Bermas - International journal of women's health, 2022 - Taylor & Francis
Systemic lupus erythematosus (SLE) affects reproductive aged women. Issues regarding
family planning are an important part of SLE patient care. Women with SLE can flare during …
family planning are an important part of SLE patient care. Women with SLE can flare during …
Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options
…, C Kyogoku, A Flechsig, AM Becker, KH Dao… - Journal of Molecular …, 2017 - Springer
Interferon alpha and its surrogates, including IP-10 and SIGLEC1, paralleled changes of
disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon …
disease activity in systemic lupus erythematosus (SLE). However, the whole blood interferon …
Nonserious infections: should there be cause for serious concerns?
KH Dao, M Herbert, N Habal… - Rheumatic Disease …, 2012 - rheumatic.theclinics.com
Although the use of biologic agents is becoming more commonplace in clinical practice,
concern for safety has been mounting. The tumor necrosis factor-alpha inhibitors (TNFi) are the …
concern for safety has been mounting. The tumor necrosis factor-alpha inhibitors (TNFi) are the …
Malignancy risks with biologic therapies
JJ Cush, KH Dao - Rheumatic Disease Clinics, 2012 - rheumatic.theclinics.com
The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction
of etanercept and infliximab, biospecific inhibitors of tumor necrosis factor (TNF) a, for …
of etanercept and infliximab, biospecific inhibitors of tumor necrosis factor (TNF) a, for …
Perceptions of pregnancy and lactation from the Pregnancy and Lactation Autoimmune Network registry
BS Mills, KH Dao, KM Tecson, EF Beil, R Tate… - The Journal of …, 2020 - jrheum.org
Objective. The Pregnancy and Lactation Autoimmune Network (PLAN) registry was
established to evaluate the concerns of women with autoimmune or inflammatory rheumatic …
established to evaluate the concerns of women with autoimmune or inflammatory rheumatic …
An unusually “complex” glomerulonephritis
…, D Savino, S Kumar, KH Dao - Baylor University …, 2022 - Taylor & Francis
A 53-year-old man with granulomatosis with polyangiitis presented with fever and acute
kidney injury with nephrotic-range proteinuria following the second dose of the mRNA COVID-…
kidney injury with nephrotic-range proteinuria following the second dose of the mRNA COVID-…
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial
RF van Vollenhoven, JF Merola, KH Dao… - 2024 - lupus.bmj.com
Objective Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2)
inhibitor approved in multiple countries for the treatment of moderate-to-severe plaque …
inhibitor approved in multiple countries for the treatment of moderate-to-severe plaque …